Help us: Donate
Follow us on:



Senolytics Reduce Gut Inflammation in Mice

Two widely known compounds may be useful in treating chronic intestinal inflammation.

A few years ago, a team at Mayo Clinic led by Dr. James Kirkland treated mice with the cancer drug dasatinib and the popular dietary supplement quercetin, with results suggesting that the combination was able to destroy senescent cells.

This combination was part of the first generation of drugs known as senolytics, compounds that encourage senescent cells to self destruct in a process known as apoptosis, thus reducing chronic inflammation and improving tissue regeneration. Senolytics are thought to be a possible way to address some of the aging process and could potentially support healthy longevity if the life extending results seen in previous mouse studies can be translated to humans.

A new preprinted study explores the long-term effects of exposure to dasatinib and quercetin (D+Q) on gut microbiome composition, senescent cell populations, and inflammation.

Until now, it was unknown what influence senolytics such as D+Q have on the populations and diversity of bacteria living in the gut microbiome. With 10 controls and 10 aged mice, the researchers examined the guts of the animals to determine how D+Q affected senescent cells in intestinal walls. They used the biomarkers p16 and p21, both of which are involved in the cell cycle process and whose elevated levels indicate the presence of senescent cells. Mice given D+Q had significantly reduced p16 and p21, suggesting a corresponding reduction of senescent cell activity and/or presence.

The researchers also investigated how D+Q influenced the presence of the inflammatory biomarkers Cxcl1, Il1Ξ², Il6, Mcp1, and TnfΞ±. The data showed that there was a reduction of these inflammatory biomarkers in the mice given D+Q.

Finally, after analysis, the team noted that there were significant differences between the microbial signatures of the mice given D+Q and the control mice. The researchers also noted that there was a direct correlation between elevated senescence and inflammation biomarkers and particular microbial signatures.

Cellular senescence contributes to age-related disorders including physical dysfunction, disabilities and mortality caused by tissue inflammation and damage. Senescent cells accumulate in multiple tissues with aging and at etiological sites of multiple chronic disorders. The senolytic drug combination, Dasatinib plus Quercetin (D+Q), is known to reduce senescent cell abundance in aged mice. However, the effects of long-term D+Q treatment on intestinal senescent cell and inflammatory burden and microbiome composition in aged mice remain unknown. Here, we examine the effect of D+Q on senescence (p16 Ink4a and p21 Cip1) and inflammation (Cxcl1, Il1Ξ², Il6, Mcp1, and TnfΞ±) markers in small (ileum) and large (caecum and colon) intestine in aged mice (n=10) compared to age-matched placebo-treated mice (n=10). Additionally, we examine microbial composition along the intestinal tract in these mice. D+Q-treated mice show significantly lower senescent cell (p16 and p21 expression) and inflammatory (Cxcl1, Il1Ξ², Il6, Mcp1 and TnfΞ± expression) burden in small and large intestine compared with control mice. Further, we find specific microbial signatures in ileal, cecal, colonic and fecal regions that are distinctly modulated by D+Q, with modulation being most prominent in small intestine. Further analyses reveal specific correlation of senescence and inflammation markers with specific microbial signatures. Together, these data demonstrate that the senolytic treatment reduces intestinal senescence and inflammation while altering specific microbiota signatures and suggest that the optimized senolytic regimens might improve health via reducing intestinal senescence, inflammation and microbial dysbiosis in older subjects.


While this is only a small study, this data suggests that senolytics may have a beneficial effect on the gut microbiome and might potentially reduce intestinal permeability and inflammation by addressing cellular senescence and modulation of the microbiome.

We would like to ask you a small favor. We are a non-profit foundation, and unlike some other organizations, we have no shareholders and no products to sell you. We are committed to responsible journalism, free from commercial or political influence, that allows you to make informed decisions about your future health.

All our news and educational content is free for everyone to read, but it does mean that we rely on the help of people like you. Every contribution, no matter if it’s big or small, supports independent journalism and sustains our future. You can support us by making a donation or in other ways at no cost to you.

Dietary Magnesium in Dementia Prevention

Researchers publishing in the European Journal of Nutrition looked into magnesium as a possible candidate for preventing dementia, focusing on...

Glycine and Cysteine Combo Rescues Cognitive Decline in Mice

Scientists publishing in Antioxidants have reported that increasing glutathione levels with GlyNAC, a supplement that combines glycine and cysteine, significantly...

Vitalik Buterin Exclusive Interview: Longevity, AI and More

Vitalik Buterin holding Zuzu, the puppy rescued by people of Zuzalu. Photo: Michelle Lai Don’t try finding Zuzalu on a...

Centenarians Have Slightly Different Gut Ecologies

Researchers publishing in Nature Microbiology have determined that the viruses populating the intestines of centenarians are slightly different from those...


[1] Saccon TD, Nagpal R, Yadav H, Cavalcante MB, Nunes ADC, Schneider A, Gesing A, Hughes B, Yousefzadeh M, Tchkonia T, Kirkland JL, Niedernhofer LJ, Robbins PD, Masternak MM. Senolytic combination of Dasatinib and Quercetin alleviates intestinal senescence and inflammation and modulates the gut microbiome in aged mice. J Gerontol A Biol Sci Med Sci. 2021 Jan 6:glab002. doi: 10.1093/gerona/glab002. Epub ahead of print. PMID: 33406219.

About the author

Steve Hill

Steve serves on the LEAF Board of Directors and is the Editor in Chief, coordinating the daily news articles and social media content of the organization. He is an active journalist in the aging research and biotechnology field and has to date written over 600 articles on the topic, interviewed over 100 of the leading researchers in the field, hosted livestream events focused on aging, as well as attending various medical industry conferences. His work has been featured in H+ magazine, Psychology Today, Singularity Weblog, Standpoint Magazine, Swiss Monthly, Keep me Prime, and New Economy Magazine. Steve is one of three recipients of the 2020 H+ Innovator Award and shares this honour with Mirko Ranieri – Google AR and Dinorah Delfin – Immortalists Magazine. The H+ Innovator Award looks into our community and acknowledges ideas and projects that encourage social change, achieve scientific accomplishments, technological advances, philosophical and intellectual visions, author unique narratives, build fascinating artistic ventures, and develop products that bridge gaps and help us to achieve transhumanist goals. Steve has a background in project management and administration which has helped him to build a united team for effective fundraising and content creation, while his additional knowledge of biology and statistical data analysis allows him to carefully assess and coordinate the scientific groups involved in the project.
  1. jimofoz
    January 10, 2021

    Steve, I seem to remember you or someone at lifespan expressing the view that dasatinib + quercetin would not have a large or muhh by effect in humans? Am I correct? And if so, why is this?

  2. jimofoz
    January 10, 2021

    Steve, I seem to remember you or someone at lifespan expressing the view that dasatinib + quercetin would not have a large or much effect at all in humans? Am I correct? And if so, why is this?

Write a comment:


Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.